Notably, a phase 1 trial with a CCR2 antagonist in non-metastatic pancreatic cancer patients demonstrated that CCR2 inhibition decreases the number of tumor-infiltrating Tregs (200). This evidence concerns the gene CCR2 and neoplasm.